KRAS testing in clinical laboratory

Optimizing targeted therapy

Leticia Miravalle, Joel A. Lefferts, Mohammad Al-Haddad, Gregory J. Tsongalis, Liang Cheng

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aim: Activating mutations in the KRAS gene are found in more than 30% of colorectal tumors, where they are associated with a poor response to anti-epidermal growth factor receptor therapies. Mutation testing techniques have therefore become an urgent concern. Several methods for KRAS mutation detection have been described in the literature. Most of these are laboratory developed tests and only a few commercial assays are currently available. Materials and Methods: We studied the performance characteristics of a KRAS mutation detection assay on the ABI-3130XL genetic analyzer using a new commercial mutation detection kit based on shifted termination assay technology. Samples were analyzed in parallel by different reference laboratories using alternative methodologies. Various sample types were used including formalin-fixed paraffin-embedded tissue, fine-needle aspirates, and cyst fluid specimens. Results: A high level of agreement (100% correlation for formalin-fixed paraffin-embedded tissue and fine-needle aspirate samples and 93% correlation for cyst fluid specimens) was obtained despite the use of different methodologies. Conclusion: Shift termination assay is a simple, robust, and sensitive method for the identification of KRAS mutations in a wide variety of specimen types.

Original languageEnglish
Pages (from-to)337-342
Number of pages6
JournalCancer Genomics and Proteomics
Volume9
Issue number5
StatePublished - Sep 2012

Fingerprint

Clinical laboratories
Assays
Mutation
Testing
Needles
Paraffin
Formaldehyde
Cyst Fluid
Tissue
Fluids
Therapeutics
Epidermal Growth Factor Receptor
Tumors
Genes
Colorectal Neoplasms
Technology

Keywords

  • Colorectal cancer
  • Fine needle aspirate
  • FNA
  • KRAS mutation
  • Molecular diagnostics
  • Personalized medicine
  • Shift termination assay
  • Targeted therapy

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Cancer Research
  • Biochemistry

Cite this

Miravalle, L., Lefferts, J. A., Al-Haddad, M., Tsongalis, G. J., & Cheng, L. (2012). KRAS testing in clinical laboratory: Optimizing targeted therapy. Cancer Genomics and Proteomics, 9(5), 337-342.

KRAS testing in clinical laboratory : Optimizing targeted therapy. / Miravalle, Leticia; Lefferts, Joel A.; Al-Haddad, Mohammad; Tsongalis, Gregory J.; Cheng, Liang.

In: Cancer Genomics and Proteomics, Vol. 9, No. 5, 09.2012, p. 337-342.

Research output: Contribution to journalArticle

Miravalle, L, Lefferts, JA, Al-Haddad, M, Tsongalis, GJ & Cheng, L 2012, 'KRAS testing in clinical laboratory: Optimizing targeted therapy', Cancer Genomics and Proteomics, vol. 9, no. 5, pp. 337-342.
Miravalle L, Lefferts JA, Al-Haddad M, Tsongalis GJ, Cheng L. KRAS testing in clinical laboratory: Optimizing targeted therapy. Cancer Genomics and Proteomics. 2012 Sep;9(5):337-342.
Miravalle, Leticia ; Lefferts, Joel A. ; Al-Haddad, Mohammad ; Tsongalis, Gregory J. ; Cheng, Liang. / KRAS testing in clinical laboratory : Optimizing targeted therapy. In: Cancer Genomics and Proteomics. 2012 ; Vol. 9, No. 5. pp. 337-342.
@article{aab15fe07aaa428483b35e0be9f81939,
title = "KRAS testing in clinical laboratory: Optimizing targeted therapy",
abstract = "Background/Aim: Activating mutations in the KRAS gene are found in more than 30{\%} of colorectal tumors, where they are associated with a poor response to anti-epidermal growth factor receptor therapies. Mutation testing techniques have therefore become an urgent concern. Several methods for KRAS mutation detection have been described in the literature. Most of these are laboratory developed tests and only a few commercial assays are currently available. Materials and Methods: We studied the performance characteristics of a KRAS mutation detection assay on the ABI-3130XL genetic analyzer using a new commercial mutation detection kit based on shifted termination assay technology. Samples were analyzed in parallel by different reference laboratories using alternative methodologies. Various sample types were used including formalin-fixed paraffin-embedded tissue, fine-needle aspirates, and cyst fluid specimens. Results: A high level of agreement (100{\%} correlation for formalin-fixed paraffin-embedded tissue and fine-needle aspirate samples and 93{\%} correlation for cyst fluid specimens) was obtained despite the use of different methodologies. Conclusion: Shift termination assay is a simple, robust, and sensitive method for the identification of KRAS mutations in a wide variety of specimen types.",
keywords = "Colorectal cancer, Fine needle aspirate, FNA, KRAS mutation, Molecular diagnostics, Personalized medicine, Shift termination assay, Targeted therapy",
author = "Leticia Miravalle and Lefferts, {Joel A.} and Mohammad Al-Haddad and Tsongalis, {Gregory J.} and Liang Cheng",
year = "2012",
month = "9",
language = "English",
volume = "9",
pages = "337--342",
journal = "Cancer Genomics and Proteomics",
issn = "1109-6535",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - KRAS testing in clinical laboratory

T2 - Optimizing targeted therapy

AU - Miravalle, Leticia

AU - Lefferts, Joel A.

AU - Al-Haddad, Mohammad

AU - Tsongalis, Gregory J.

AU - Cheng, Liang

PY - 2012/9

Y1 - 2012/9

N2 - Background/Aim: Activating mutations in the KRAS gene are found in more than 30% of colorectal tumors, where they are associated with a poor response to anti-epidermal growth factor receptor therapies. Mutation testing techniques have therefore become an urgent concern. Several methods for KRAS mutation detection have been described in the literature. Most of these are laboratory developed tests and only a few commercial assays are currently available. Materials and Methods: We studied the performance characteristics of a KRAS mutation detection assay on the ABI-3130XL genetic analyzer using a new commercial mutation detection kit based on shifted termination assay technology. Samples were analyzed in parallel by different reference laboratories using alternative methodologies. Various sample types were used including formalin-fixed paraffin-embedded tissue, fine-needle aspirates, and cyst fluid specimens. Results: A high level of agreement (100% correlation for formalin-fixed paraffin-embedded tissue and fine-needle aspirate samples and 93% correlation for cyst fluid specimens) was obtained despite the use of different methodologies. Conclusion: Shift termination assay is a simple, robust, and sensitive method for the identification of KRAS mutations in a wide variety of specimen types.

AB - Background/Aim: Activating mutations in the KRAS gene are found in more than 30% of colorectal tumors, where they are associated with a poor response to anti-epidermal growth factor receptor therapies. Mutation testing techniques have therefore become an urgent concern. Several methods for KRAS mutation detection have been described in the literature. Most of these are laboratory developed tests and only a few commercial assays are currently available. Materials and Methods: We studied the performance characteristics of a KRAS mutation detection assay on the ABI-3130XL genetic analyzer using a new commercial mutation detection kit based on shifted termination assay technology. Samples were analyzed in parallel by different reference laboratories using alternative methodologies. Various sample types were used including formalin-fixed paraffin-embedded tissue, fine-needle aspirates, and cyst fluid specimens. Results: A high level of agreement (100% correlation for formalin-fixed paraffin-embedded tissue and fine-needle aspirate samples and 93% correlation for cyst fluid specimens) was obtained despite the use of different methodologies. Conclusion: Shift termination assay is a simple, robust, and sensitive method for the identification of KRAS mutations in a wide variety of specimen types.

KW - Colorectal cancer

KW - Fine needle aspirate

KW - FNA

KW - KRAS mutation

KW - Molecular diagnostics

KW - Personalized medicine

KW - Shift termination assay

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84867386749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867386749&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 337

EP - 342

JO - Cancer Genomics and Proteomics

JF - Cancer Genomics and Proteomics

SN - 1109-6535

IS - 5

ER -